XSHE
300298
Market cap1.33bUSD
Oct 09, Last price
16.68CNY
1D
4.25%
1Q
14.80%
Jan 2017
32.41%
IPO
161.91%
Name
Sinocare Inc
Chart & performance
P/E
100.25
P/S
1.99
EPS
0.17
Div yield, %
1.38%
Shrs. gr., 5y
-0.29%
Rev. gr., 5y
18.25%
Revenues
4.66b
+4.87%
Net income
93m
-71.61%
CFO
605m
-4.14%
Dividend
Jun 13, 20250.22 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sinocare Inc. engages in the development, manufacture, and marketing of rapid diagnosis testing products primarily in the People’s Republic of China. It offers blood glucose and pressure monitors; point of care testing products; digital management tool solutions; non-invasive screening products; and PTS and Trividia products. The company provides its products for the patients with chronic diseases and diabetes, as well as for healthcare professionals. It also exports its products. The company was founded in 2002 and is based in Changsha, the People’s Republic of China.
Key people
Xinyi Li
Vice Chairman of the Board, General Manager · since 2025
Zhuzi He
Chief Financial Officer · since 2023
Shaobo Li
Chairman of the Board · since 2025
Shimin Wang
Deputy General Manager · since 2013
Jiyun Zheng
Deputy General Manager, Secretary of the Board · since 2023
Hongjing Che
Director · since 2015
Jizheng Chen
Independent Director · since 2022
Jianyou Tan
Independent Director · since 2025
Headquarters & legal address
长沙高新技术产业开发区谷苑路265号
长沙市, HN 410000
CN
长沙市, HN 410000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||